AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- Details
- Category: Bayer

European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
- Details
- Category: Pfizer

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Details
- Category: Bayer

The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen.
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
- Details
- Category: Bayer

Bayer and Aignostics to collaborate on next generation precision oncology
- Details
- Category: Bayer

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
- Details
- Category: AstraZeneca

The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.
European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
- Details
- Category: Pfizer

More Pharma News ...
- Novartis presents new data on safety and efficacy of Zolgensma
- Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
- Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
- European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis
- Acquisition of Icosavax completed
- First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
- Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor